Integrated Immunopeptidomic and Proteomic Analysis of COVID-19 lung biopsies.

Saved in:
Bibliographic Details
Title: Integrated Immunopeptidomic and Proteomic Analysis of COVID-19 lung biopsies.
Authors: Yin S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Klaeger S; Broad Institute of MIT and Harvard, Cambridge, MA, United States., Chea VA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, United States., Carulli IP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, United States., Rachimi S; Broad Institute of MIT and Harvard, Cambridge, MA, United States., Black KE; Harvard Medical School, Boston, MA, United States.; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, United States., Filbin M; Harvard Medical School, Boston, MA, United States.; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, United States., Hariri LP; Harvard Medical School, Boston, MA, United States.; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, United States.; Department of Pathology, Massachusetts General Hospital, Boston, MA, United States., Knipe RS; Harvard Medical School, Boston, MA, United States.; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, United States., Padera RF; Harvard Medical School, Boston, MA, United States.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States., Stevens JD; Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States., Lane WJ; Harvard Medical School, Boston, MA, United States.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States., Carr SA; Broad Institute of MIT and Harvard, Cambridge, MA, United States., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Broad Institute of MIT and Harvard, Cambridge, MA, United States.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States., Kim EY; Harvard Medical School, Boston, MA, United States.; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, United States., Keskin DB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Broad Institute of MIT and Harvard, Cambridge, MA, United States.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, United States.; Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.; Department of Computer Science, Metropolitan College, Boston University, Boston, MA, United States.
Source: Frontiers in immunology [Front Immunol] 2023 Oct 20; Vol. 14, pp. 1269335. Date of Electronic Publication: 2023 Oct 20 (Print Publication: 2023).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1269335